Indivior PLC

#Opioid Use Disorder #Addiction Medicine #CNS

Indivior PLC (NASDAQ: INDV) is a specialty pharmaceutical company singularly focused on opioid use disorder (OUD), developing and commercializing evidence-based treatments such as the once-monthly injection Sublocade to support long-term recovery.

Company Info

Sector:Specialty Pharmaceuticals

Headquarters:Slough, England, UK

Founded:2014

Website:www.indivior.com/

Upcoming Milestones & Key Dates

Q4 2026

Corporate

Expected close of all-stock merger with Supernus Pharmaceuticals

Q3 2026

Financial

Third quarter 2026 financial results

Clinical Development Pipeline

Sublocade (buprenorphine extended-release)

Target: Mu-opioid receptor partial agonist

Opioid use disorder

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Perseris (buprenorphine)

Target: Mu-opioid receptor partial agonist

Opioid use disorder

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Opvee (nalmefene)

Target: Opioid receptor antagonist

Opioid overdose reversal

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Joe Ciaffoni

Chief Executive Officer

Ryan Preblick

Chief Financial Officer

Dr. Ann Wheeler

Chief Medical Officer

Careers & Job Openings

See all open roles

Multiple Departments

See careers page

Apply Now →